E
Eri Arai
Researcher at University of Pennsylvania
Publications - 7
Citations - 262
Eri Arai is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Homologous recombination & DNA repair. The author has an hindex of 5, co-authored 7 publications receiving 80 citations.
Papers
More filters
Journal ArticleDOI
In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer.
Zeyu Chen,Eri Arai,Omar Khan,Zhen Zhang,Shin Foong Ngiow,Yuan He,Hua Huang,Sasikanth Manne,Zhendong Cao,Amy E. Baxter,Zhangying Cai,Elizabeth Freilich,Mohammed Alkhatim A. Ali,Josephine R. Giles,Jennifer E. Wu,Allison R. Greenplate,Mohamed A. Hakeem,Qingzhou Chen,Makoto Kurachi,Kito Nzingha,Viktoriya Ekshyyan,Divij Mathew,Zhuoyu Wen,Nancy A. Speck,Alexis Battle,Shelley L. Berger,E. John Wherry,Junwei Shi +27 more
TL;DR: In this paper, the authors developed an in-vivo T-cell CRISPR screening platform and identified a key mechanism restraining TEFF biology through the ETS family TF, Fli1.
Journal ArticleDOI
ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination-deficient cells
Priyanka Verma,Yeqiao Zhou,Zhendong Cao,Peter V. Deraska,Moniher Deb,Eri Arai,Weihua Li,Yue Shao,Laura N. Puentes,Yiwen Li,Sonali Patankar,Robert H. Mach,Robert B. Faryabi,Junwei Shi,Roger A. Greenberg +14 more
TL;DR: Using a CRISPR-based screen, this article identified the PAR-binding chromatin remodeller ALC1/CHD1L as a key determinant of PARPi toxicity in HR-deficient cells.
Posted ContentDOI
ALC1 links chromatin accessibility to PARP inhibitor response in homologous recombination deficient cells
Priyanka Verma,Yeqiao Zhou,Zhendong Cao,Peter V. Deraska,Moniher Deb,Eri Arai,Weihua Li,Yue Shao,Yiwen Li,Laura N. Puentes,Sonali Patankar,Robert H. Mach,Robert B. Faryabi,Junwei Shi,Roger A. Greenberg +14 more
TL;DR: Using a CRISPR based screen, this work identifies the PAR-binding Snf2-like ATPase, ALC1/CHD1L, as a key determinant of PARPi toxicity in HR-deficient cells, and establishes PAR-dependent chromatin remodeling as a mechanistically distinct aspect ofPARPi responses, implicating A LC1 inhibition as a new approach to overcome therapeutic resistance in HR -deficient cancers.
Journal ArticleDOI
Genetic screening for single-cell variability modulators driving therapy resistance
Eduardo A. Torre,Eri Arai,Sareh Bayatpour,Connie L. Jiang,Lauren E. Beck,Benjamin L. Emert,Sydney M. Shaffer,Ian A. Mellis,Mitchell Fane,Gretchen M. Alicea,Krista A. Budinich,Ashani T. Weeraratna,Junwei Shi,Arjun Raj +13 more
TL;DR: In melanoma, transient fluctuations in the molecular state of tumor cells mark the formation of rare cells primed to survive BRAF inhibition and reprogram into a stably drug-resistant fate as discussed by the authors.
Journal ArticleDOI
Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis
Jonathan J. Ipsaro,Chen Shen,Eri Arai,Yali Xu,Yali Xu,Justin B. Kinney,Leemor Joshua-Tor,Leemor Joshua-Tor,Christopher R. Vakoc,Junwei Shi +9 more
TL;DR: This method takes advantage of the heterogeneous in-frame alleles produced following Cas9-mediated DNA cleavage to generate rare alleles that confer resistance to the growth-arrest caused by chemical inhibitors and identifies novel resistance alleles of two lysine methyltransferases, DOT1L and EZH2, which are each essential for the growth of MLL-fusion leukemia cells.